Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

Post-Hospital Suicide Prevention Intervention for Patients With Schizophrenia-Spectrum Disorders

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04221269

Acronym

CLASP-S

Enrollment

Registered

2020-01-09

Start date

2020-12-01

Completion date

2023-06-01

Last updated

2023-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, Suicide

Keywords

psychiatric hospitalization, suicide prevention, psychosis, psychosocial intervention

Brief summary

The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.

Interventions

BEHAVIORALEnhanced Treatment as Usual

Routine community care plus assessment feedback reports to clinicians.

BEHAVIORALCoping Long-term with Active Suicide Program for Schizophrenia

Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* suicidal thoughts or behaviors prior to hospital admission * diagnosis of a schizophrenia-spectrum disorder * receiving pharmacotherapy * 18 years or older * speaks/reads English

Exclusion criteria

* psychosis due to substance use or medical condition * lack of phone access * discharge to long-term facility

Design outcomes

Primary

Measure	Time frame	Description
Client Satisfaction Questionnaire	6 months	The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.

Secondary

Measure	Time frame	Description
Columbia Suicide Severity Rating Scale	6 months	The Columbia Suicide Severity Rating Scale is an interviewer-rated measure of suicidal thoughts and behaviors. The total score (sum of items) will be used and ranges from 2 to 25 with higher scores indicating higher suicidal thoughts and behaviors.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026